Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2015 Jun;30(4):421-30.
doi: 10.1177/1533317514556874. Epub 2014 Nov 11.

Testosterone treatment of men with mild cognitive impairment and low testosterone levels

M M Cherrier  1 , K Anderson  2 , J Shofer  3 , S Millard  3 , A M Matsumoto  4
Affiliations
Randomized Controlled Trial

Testosterone treatment of men with mild cognitive impairment and low testosterone levels

M M Cherrier et al. Am J Alzheimers Dis Other Demen. 2015 Jun.

Abstract

Introduction: This study investigated the effects of testosterone (T) treatment on cognition, mood, and quality of life in men with mild cognitive impairment (MCI) and low serum T levels.

Methods: A total of 351 community-dwelling men were screened, and 37 men evidenced both MCI and low T of whom 27 agreed for further screening. Twenty-two met all the study inclusion/exclusion criteria and enrolled in a 6-month randomized, double-blind, placebo-controlled study.

Results: Total T levels significantly increased in the T treatment group. No significant changes were observed in measures of cognition, mood, or quality of life other than improvement in 1 objective measure of verbal memory (P < .05) and decreased depression symptoms (P < .02) in the treatment group.

Conclusions: Testosterone treatment may modestly improve verbal memory and depression symptoms in men with both MCI and low T.

Keywords: cognition; low serum testosterone; mild cognitive impairment; quality of life; testosterone treatment; verbal memory.

PubMed Disclaimer

Conflict of interest statement

The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Figures

Figure 1.
Figure 1.
CONSORT flow diagram indicating number of study participants and reasons for drop outs at each stage of screening, enrollment, and study completion.
See this image and copyright information in PMC

References

    1. Hogervorst E, Bandelow S, Combrinck M, Smith AD. Low free testosterone is an independent risk factor for Alzheimer's disease. Exp Gerontol. 2004;39 (11-12):1633–1639. - PubMed
    1. Moffat SD, Zonderman AB, Metter EJ, Smith AD. Free testosterone and risk for Alzheimer disease in older men. Neurology. 2004;62 (2):188–193. - PubMed
    1. Chu LW, Tam S, Lee PW, et al. . Bioavailable testosterone is associated with a reduced risk of amnestic mild cognitive impairment in older men. Clin Endocrinol (Oxf). 2008;68 (4):589–598. - PubMed
    1. Chu LW, Tam S, Wong RL, et al. . Bioavailable testosterone predicts a lower risk of Alzheimer's disease in older men. J Alzheimers Dis. 2010;21 (4):1335–1345. - PubMed
    1. Morley JE, Kaiser F, Raum WJ, et al. . Potentially predictive and manipulable blood serum correlates of aging in the healthy human male: Progessive decreases in bioavailable testosterone, dehydroepiandrosterone sulfate, and the ratio of insulin-like growth factor to 1 growth hormone. Proc Natl Acad Sci U S A. 1997;94 (14):7537–7542. - PMC - PubMed

Publication types